The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
NCRI 2019 | CAR T-cell therapy for B-cell lymphomas: a focus on improving CR
Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, highlights the focus on improving CR rates in patients treated with CAR T-cell therapy as strong persistence and duration of response have already been achieved. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.
